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Abstract
Paclitaxel (PTX) and docetaxel (DTX) are key members of taxenes with high anti-tumor 
activity against various cancer cells. These chemotherapeutic agents suffer from a number of 
drawbacks and it seems that low solubility in water is the most important one. Although much 
effort has been made in improving the bioavailability of PTX and DTX, the low bioavailability 
and minimal accumulation at tumor sites are still the challenges faced in PTX and DTX therapy. 
As a consequence, biomaterial-synthesized NPs have attracted much attention due to unique
properties. Among them, chitosan (CS) is of interest due to its great biocompatibility. CS is a
positively charged polysaccharide with the capability of interaction with negatively charged
biomolecules. Besides, it can be processed into the sheet, micro/nano-particles, scaffold, and 
is dissolvable in mildly acidic pH similar to the pH of the tumor microenvironment. Keeping 
in mind the different applications of CS in the preparation of nanocarriers for delivery of PTX 
and DTX, in the present review, we demonstrate that how CS functionalized-nanocarriers and 
CS modification can be beneficial in enhancing the bioavailability of PTX and DTX, targeted
delivery at tumor site, image-guided delivery and co-delivery with other anti-tumor drugs or
genes.
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DTX-C-G/P, DTX-loaded thermos-responsive CS/b-glycerophosphate hydrogel;  
GSH, glutathione;  
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pDNA, plasmid DNA;  
DOX, doxorubicin;  
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ACHC, Alg coated CS hollow nanosphere;  
CNT, carbon nanotube;  
BB, berbamine;
LDL, low density lipoprotein;  
NSC, N-succinyl CS;  
LA, lipoid acid;  
IGF-1R, insulin-like growth factor receptor-1;  
MUC1, mucin-1;  
CS-AuNPs, CS-stabilized gold NPs;  
PAI, photoacoustic imaging;  
DMC, 3,6-O,O/-dimyristoyl CS;  
SLNs, solid lipid NPs;  
CDs, cyclodextrins. 
1. Introduction
Driven from the second most abundant polysaccharide, chitin, chitosan (CS) is a low-
cost biomaterial which its favorable characteristics have turned in into one of the most 
explored biomaterials. CS-based materials have been used in the versatile area 
including biological medicine [1-3]. The first mention of the inveterate extraction of 
chitin backed to 1799 by Hatchett, but its discovery attributed to Braconnot, twelve years 
later, who extracted it from fungi [4]. Chitin has been extracted mostly from crustaceans 
and fungi, but its extraction from insects and vertebrates are also reported [5]. The research 
by Rouget in 1859 resulted in the discovery of CS, the most important derivative of chitin, 
which is obtained by the deacetylation of chitin, removing the acetamido groups leaving the 
free amino groups. CS is regarded as a random co-polymer of ɣ-glucosamine and N-acetyl-
ɣ-glucosamine units linked with β(1,4) - glycosidic bonds, providing the polymer with two 
functional groups, hydroxyl, and amine, and overall positive charge. It is dissolvable in mild 
acidic condition, naturally gellable with pH, can be processed into sheet, micro/nano-
particles, scaffold, can be chemically modified via its functional groups, can interact with 
negatively charged biomolecules and cell surface because of its positive charge [6, 7], 
enzymatically degradable [8], generally non-cytotoxic, biocompatible and having 
antibacterial effects. Owing to its bio-friendly characteristics, CS-based materials have 
been applied in multiple fields of medicine including replacement/ supplemental to tissue
(dental, bone and cartilage, wound healing, regenerative medicine) [9-11], as carrier 
and delivery vehicle for biomolecule cargo (targeted drug delivery, stimuli-response 
release) [12, 13], cell encapsulation/ cell delivery [14], and 3D bioprinting [15]. As drug 
carriers, CS-based materials have been developed as micro/nano-particles based on 
crosslinking the CS in the presence of cargo. This process can be approached via developing 
surfactant-stabled CS droplets in water/oil emulsion followed by crosslinking CS, coacervation 
of aqueous acidic CS solution in alkaline, spray-drying of CS solution, ionotropic gelation of 
CS in a bath of polyanion solution, and reverse micellar methods [16, 17]. Crosslinking could 
be performed either covalently, e.g. using glutaraldehyde [18], or physically, e.g. using 
polyanions [19]. The size and size distribution of NPs being controlled by the concentration 
and molecular weight of reactants, stirring speed, duration of process, pH and temperature of 
solutions [20, 21].
2. Paclitaxel and docetaxel
Finding an effective way to cure cancer, the leading cause of death on a worldwide scale, is 
still a challenge [22]. The rate of cancer incidence is significantly increased for the past few 
years, probably due to the exposure to potentially toxic agents [23-26]. However, 
nanotechnology techniques and methods can help to increase the efficiency of the drug 
delivery and releasing control in the tumor sites [27]. The conventional chemotherapeutic 
agents such as paclitaxel (PTX) (PubChem CID: 36314) [28] and docetaxel (DTX) (PubChem 
CID: 148124) [29] have been loaded on nanostructures to improve their potential in 
chemotherapy [30, 31]. PTX with chemical formula of C47H51O41 (figure 1) [32] is 
one of the most common therapeutic compounds extensively applied for treatment of a 
number of cancers such as lung cancer [33], ovarian cancer [34], brain tumors [35], cervical 
cancer [36], breast cancer [37] and colorectal cancer [38]. The discovery of PTX returns to 
1963 when it was isolated from the bark of the pacific yew Taxus brevifolia [39]. in 1992, the 
Food and Drug Administration (FDA) confirmed the application of PTX for cancer therapy 
[40]. As a semisynthetic plant alkaloid, PTX belongs to the category of Taxanes s that 
restabilize the microtubule cytoskeleton against depolymerization (figure 2) [41]. As one of the 
key members of the cytoskeleton, microtubules play a remarkable role in a variety of biological 
processes including preservation of cell shape, molecular signaling pathways, contributing in 
the transportation of cell organelles and more import the antly, generation of the mitotic 
spindle for ensuring the progression of the cell cycle [42-45]. PTX impacts the cell division via 
promoting the polymerization of the tubulin proteins and production of non-functional 
microtubules [46]. DTX, another member of taxanes, is extensively used for cancer treatment 
as well (figure 1) [47-51]. This chemotherapeutic compound was first introduced in 1990 from 
the European yew tree, Taxus baccata [52]. Similar to PTX, DTX also stabilizes the 
microtubules and disrupts the microtubule dynamics which leads to mitosis prevention 
and cell proliferation [53]. FDA approved the application of DTX for the treatment of cancer 
in 1996 [54]. Despite its potential of anti-tumor activities, DTX is a lipophilic agent with low 
solubility in water which restricts its efficiency [47, 55, 56]. The current formulation of the 
DTX contains ethanol has an adverse impact on its bioavailability [47, 55, 56]. In this 
context, nano-techniques can be a promising approach to improve the bioavailability of DTX 
with no side effects on healthy cells or tissues. In spite of the efficient benefits of 
phytoconstituents, they show some of the challenges such as limited knowledge of 
pharmacokinetic profiles and the requirement of high doses that are usually associated with 
toxicity [57, 58]. Over recent years, the use of new drug delivery systems such as encapsulation 
of herbal ingredients with nanoparticles would likely affect the stability and
pharmacokinetics of the carried compounds [59]. In the case of PTX and DTX, there are some
challenges such as low water solubility (0.3 μg/mL), presystemic metabolism, high 
protein binding, high affinity to P-glycoprotein (P-gp), and some adverse effects which lead 
to their low bioavailability [60, 61]. In this study, a broad range of biocompatible, 
biodegradable, and nontoxic polymeric nanoparticles, micelles, and nanotubes were 
introduced to improve the pharmacokinetic profiles of DTX and PTX to increase the 
solubility, bioavailability, and intracellular accumulation to tumors cells.
3. Chitosan nanocarriers  
3.1. Chitosan nanoparticles for PTX delivery
Glioblastoma is a malignant brain tumor with high prevalence and surgery is considered as the
best option in glioblastoma therapy [62]. However, patients with glioblastoma have a 
low survival time (< 2 years). The possibility of recurrence is at the highest rate in glioblastoma 
and anti-tumor drugs should effectively eliminate cancer cells. In order to provide 
efficient anti-glioblastoma therapy, targeted delivery of chemotherapeutic agents such as 
PTX is of interest. PTX-loaded CS NPs have demonstrated great potential in the treatment 
of glioblastoma by providing a prolonged release of the drug, improving drug 
bioavailability, enhancing hemocompatibility and more importantly, exerting more 
cytotoxic effect compared to the PTX alone [63]. Higher cellular uptakes/efficacy of the 
nanoformulation of PTX elucidated that 1,3β-Glucan shell of the core NPs actively targeted 
various overexpressed receptors on both glioma stem cell lines (C6) and glioma cancer cell 
line (LN-18). Due to the dose-dependent toxicities of PTX [64], nanocarriers can provide a 
platform for enhancing the anti-tumor activity of PTX and simultaneously, reducing its toxicity 
by loading a low amount of drug on NPs [65]. Making an increase in the EE% and loading 
efficiency of PTX in NPs are obtained via developing novel strategies in the synthesis of 
NPs. It appears that the emulsification-crosslinking method in a W/O emulsion system can 
be considered as a smart strategy in preparation of CS NPs [66], as the resulting NPs 
demonstrated excellent loading efficiency (8.55%) and EE% (94.01%) with high
biocompatibility.
Jiang et al. have examined the efficacy of CS hollow NPs (CHN) for the delivery of PTX in 
lung cancer [67]. The limited space of a nanometer-scale hollow structure was used in 
order to enhance the water solubility, preventing drug crystallinity, and diminishing the 
particle size. Notably, the resulting CHN had a diameter size of about 200 nm that was lower 
compared to the previously reported particle sizes. The high biodegradability of CHN led to 
the release of PTX after their uptake by A549 cells, resulting in apoptotic cell death and 
consequently, reduced viability and malignancy of cancer cells. While PTX has been 
applied for the treatment of a variety of cancer, its dose-dependent toxicity is still a challenge 
which could be addressed using nanocarriers as they can enhance the targeted delivery of PTX 
to the tumor site by delivering a low amount of the PTX hence reduces the toxicity side effects 
in healthy neighbor cells. To date, the prepared CS NPs for delivery of PTX have 
demonstrated excellent properties in terms of biocompatibility, targeted delivery, 
biodegradability at the tumor site and cellular uptake. Besides, PTX-loaded CS NPs have 
dramatically diminished the viability, proliferation, and migration of cancer cells by 
induction of apoptotic cell death [68-79].
3.2. Chitosan nanoparticles for DTX delivery
Breast cancer with high malignancy and recurrence, which are two important features of this
condition, is one of the most life-threatening threatening illnesses in women [80-83]. CS NPs 
can improve the chemotherapeutic efficiency of DTX due to its excellent drug entrapment (65-
76%) and sustained-release behavior of CS which significantly inhibits the viability and 
proliferation of MDA-MB-231 breast cancer cells [84]. Moreover, breast cancer cells 
treated with encapsulated DTX in CS NPs showed a higher ratio of Bax (an apoptotic factor) 
over the BCL-2 (a down regulator of anti-apoptotic) compared to the cells treated with non-
capsulated DTX [85].
Colorectal cancer (CRC), is another lead life-threatening illness in Europe and Asia [86, 
87]Therefore, improving the efficacy of chemotherapy is of importance in improving the 
survival time of patients with CRC. Badran et al have investigated the anti-tumor activity of 
DTX CS-coated poly (lactic-co-glycolic acid) (PLGA)/polycaprolactone (PCL) NPs 
[88]. These nanocarriers have demonstrated significant drug entrapment efficiency (EE%) 
(PCL NPs: 67.1% and PLGA NPs: 76.2%), increasing the cytotoxicity potential of DTX, as 
well as the decreasingthe cell growth up to 50%. Moreover, PLGA/PCL NPs can increase the 
bioavailability of the DTX by about 4 times higher. One of the most challenging 
problems in the delivery of chemotherapeutic agents in the low biocompatibility of 
synthesized NPs which was addressed by Balavigneswaran et al. through conjugation of star-
shaped poly (d, 1-lactide)-b-gelatin (ss-pLG) into biodegradable poly (lactic acid) (PLA). On 
the other hand, the ss-pLG scaffold provides the burst release of DTX [89]. CS NPs 
demonstrate high EE% and prolonged-release behavior, and simultaneously, improve the 
intestinal permeation of DTX [90].
4. Chitosan micelles for PTX delivery
It has been shown that micelles are potential candidates in enhancing the bioavailability of 
drugs with low aqueous solubility [91, 92]. As core-shell NPs spontaneously generated in water 
from amphiphilic molecules, micellar NPs are able to protect drugs from degradation [93, 94]. 
These excellent properties have led to the extensive application of micelles for delivery of 
PTX, an anti-tumor compound with low water solubility. CS micellar NPs are capable of 
releasing PTX in prolonged-release behavior [95]. PTX-loaded CS micelles remarkably 
enhance the anti-cancer effect of PTX without influencing its cytotoxicity and simultaneously, 
improve the distribution of PTX in tissues including liver, spleen, lung, and kidney [96]. 
However, it has been reported that the levels of CS micellar NPs are higher in the liver and 
spleen compared to the heart and kidney [97].
The resistance of cancer cells to chemotherapy is still a challenge. Recently, Jin et al have
investigated the potential of PTX-loaded N-octyl-O-sulfate CS (NOSC) micelles for decreasing
the viability and proliferation of resistant tumor cells [98]. It was found that PTX-loaded NOSC
micelles: 1) increase the accumulation of PTX at the tumor site, and 2) enhance the residence
time of PTX. High accumulation of PTX at the tumor site is a result of using NOSC, so that
NOSC exerts an inhibitory impact on the P-glycoprotein (P-gp) by induction of P-gp ATPase 
to suppress the binding of PTX with P-gp, leading to the entering of PTX into cancer cells 
and simultaneously, decrease the fluidity of cell membrane. P-gp is involved in the 
inhibition of entering of chemotherapeutic agents into cells [99] and P-gp inhibition by NOSC 
facilitates the entering of PTX into tumor cells. Moreover, an increase in the incidence time of 
PTX by NOSC micellar NPs is due to the efficacy of these nanocarriers in intracellular 
delivery, drug loading, tumor targetability and increasing the stability of the drug. These 
excellent properties have led to the enhanced cytotoxicity of PTX-loaded NOSC micellar NPs 
against resistant hepatocellular carcinoma cells. In order to promote the targetability of 
NOSC NPs, a polyethylene glycol (mPEG) group can be added. Besides, the mPEG group 
leads to a decrease in the removal of CS micellar NPs by the reticuloendothelial system (RES) 
[100]. These studies highlight this fact that PTX has a low bioavailability which restricts its 
anti-tumor activity and enhancing the dose of PTX is associated with increased toxicity 
of PTX. Moreover, using a high amount of a chemotherapeutic agent such as PTX 
elevates the chance of resistance of cancer cells that consequently, decreases the 
efficacy of chemotherapy. It seems that CS micellar NPs are potential candidates to 
improve the bioavailability and anti-tumor potential of PTX. Besides, CS micelles are capable 
of diminishing the toxicity of PTX by loading a low amount of PTX on NPs. In contrast to 
CS NPs, CS micelles have been designed based on targeting tumor receptors such as P-gp or 
integrin receptors to promote the entering of PTX into cancer cells [101-110]. However, more 
studies are required to develop CS micelles targeting surface receptors and this capability 
should be considered for CS NPs. 
5. Chitosan microstructures for PTX and DTX delivery
Various therapeutic agents with different sizes can be loaded on microspheres to improve their
bioavailability [111-113]. A variety of strategies are applied in order to administer therapeutic-
loaded microspheres. However, microspheres are mainly delivered through subcutaneous 
and intramuscular routes [114-116]. Microspheres are particles with the size at the range of 5-
15 ฀m and the development of microsphere induced a dramatic evolution in 
enhancing the bioavailability of anti-tumor drugs by providing a prolonged-release behavior 
[117]. Moreover, decreasing adverse impacts and providing targeted delivery are among 
the other beneficial effects of using microspheres for drug delivery [118]. Wang and 
colleagues have investigated the potential of DTX-loaded CS microspheres for the delivery 
of the drug to the lungs [119]. A water-in-oil emulsification method was used to 
synthesize glutaraldehyde crosslinked microspheres. The resulting microspheres 
demonstrated excellent properties such as spherical shape, smooth surface, high EE% 
(88.1%) and drug loading (18.7%). These carriers had excellent biocompatibility with 
the capability of releasing a drug in a sustained-release behavior. In the case of PTX, the 
efficacy of CS-modified PLGA NPs with the capability of transient formation of 
microaggregates has been evaluated for lung delivery [120]. The modification of NPs by CS 
led to remarkable alterations in the properties of PLGA NPs so that after contacting plasma, 
the particle size of NPs enhanced from 200-300 nm to 2670 nm. However, this increase was 
reversed after 5 min and the mean particle size of CS-modified PLGA NPs returned to 350.7nm. 
Besides, CS modification provided a positive zeta potential, high cellular uptake and
enhanced cytotoxicity against lung cancer cells (A549 cells). The in vivo experiment 
manifested a significant change in the CS-modified PLGA NPs so that upon the 
administration of NPs through the tail vein, an increase in trapping in lung capillaries and 
uptake by endothelial cells occurred due to the formation of microaggregates in the 
bloodstream. To date, two studies have examined the potential of CS-modified 
microspheres for delivery of PTX and DTX, demonstrating that there is still a long way 
for further investigations [119]. The incredible role of CS modification is undeniable, so that 
conjugation of CS is associated with high cellular uptake and cytotoxicity against cancer cells. 
6. Chitosan hydrogels for PTX delivery
A three-dimensional network generated from hydrophilic agents is defined as hydrogels [121,
122]. The aim of the production of hydrogels is to form insoluble polymer matrices. These
water-swollen networks are capable of loading a high concentration of water without being
dissolved in water. Hydrogels have a number of benefits such as adjustable stiffness 
and excellent biocompatibility, leading to their tremendous applications in biomedicine [123-
125]. Notably, CS-modified hydrogels have demonstrated great potential in releasing 
drugs in a prolonged-release behavior, resulting in their usefulness for the delivery of 
chemotherapeutic agents such as PTX in cancer therapy [126, 127]. An essential 
advantage of hydrogels is providing a nanocomposite to load other therapeutics. This 
strategy diminishes the need for the anti-tumor drug, and by reducing the concentration of 
the medicine, the chance of resistance decreases, while the inhibitory effect on the growth and 
viability of cancer cells is high. In line with this strategy, Zhang and colleagues designed 
nanocomposite hydrogel for loading gold nanorods (GNR) and PTX-loaded CS micelles 
(PTX-M) in photothermal-chemotherapy [128]. The synthesized thermo-sensitive hydrogel 
matrix effectively delivered GNR and PTX-M at the tumor site. Exposing to laser ablation 
produced GNR-mediated photothermal damage. However, some tumor cells may rescue from 
photothermal therapy. In order to maximize the anti-tumor treatment, the PTX-M was loaded 
on nanocomposite hydrogel. These nanocarriers released PTX in a sustained-release 
behavior, resulting in the elimination of cancer cells evaded from photothermal 
ablation. 
7. Stimuli-responsive chitosan nanoparticles for PTX and DTX delivery
7.1. pH-responsive chitosan nanoparticles
Stimuli-responsive NPs have opened a new perspective in cancer therapy. This is due to 
the alteration of pH in the tumor microenvironment. CS-functionalized NPs coated with 
polymers are able to release PTX in a prolonged-release behavior (figure 3) [129]. These 
CS-coated polymer NPs (CPNPs) have a PLGA core, to load and retain drugs, covered by a 
polydopamine. In order to functionalize NPs, CS modification was performed through the 
polydopamine layer to functionalize NPs. CPNPs released PTX in a sustained release behavior 
so that 80% of PTX was released during 48 h. Because of the mild acidic nature of CS (PKa 
of 6.5), the CPNPs are in non-ionized form at mild acidic pHs (of around 6.5) hence 
relatively soluble and diffusive through the lipidic membrane of cells. Due to this fact, 
CPNPs demonstrated higher delivery of drugs at a mildly acidic pH of the tumor 
microenvironment (pH=6) compared to the slightly basic extracellular environment of normal 
tissues (pH=7.4) [130]. There is a difference in the pH of the tumor microenvironment 
(pH=6.3-6.8) and endosomes or lysosomes (pH=5) [131]. It seems that pH-responsive 
NPs start releasing the drug after entering to the tumor microenvironment. So, it 
is necessary to release the drug in a sustained release behavior to ensure the delivery of 
the drug into cancer cells. N-octyl-N-(2-carboxylbenzoyl) CS (OCBCS) can produce micellar 
NPs with the capability of encapsulating PTX and delivering at a prolonged release behavior 
[132]. The pH-responsive NPs play a more important role during oral administration 
of anti-tumor drugs. These NPs should be able to effectively release a drug in the intestine 
while protecting the drug from degradation in the stomach. Carboxymethyl
CS/phospholipid bilayer-capped mesoporous carbon NPs are useful nanocarriers in the 
delivery of anti-tumor drugs such as DTX [133]. These nanocarriers are composed of three 
individual parts: A) a mesoporous carbon nano matrix [131] for drug loading; B) a 
positively charged phospholipid (PL) layer providing the sustained release of a drug and C) 
a negatively charged carboxymethyl CS (CCS) provides pH-responsive drug release. 
pH=1.2 and pH=6.8 were selected to mimic the pH of gastric and intestinal fluids, 
respectively. Up to 80% of DTX release occurred in pH=6.8, demonstrating the potential of 
these nanocarriers for oral delivery. The slight decline in the pH of the tumor extracellular 
environment (6.5) and its similarity to the pKa of CS made CS-based materials suitable for 
drug carriers in chemotherapy for targeted delivery into cancerous tissues. The carrier can be 
engineered to release the drug when exposed to the pH gradient of the tumor not normal tissue. 
7.2. Thermo-responsive chitosan nanoparticles
Thermo-responsive nanocarriers are another great option for the delivery of PTX and DTX. 
One of the difficulties in PTX therapy is the formation of PTX crystals associated with 
decreased anti-tumor potential of PTX. The application of PLGA microparticles and CS 
thermo-responsive gels is beneficial in the inhibition of PTX crystallization [134]. It has been 
demonstrated that in order to provide high anti-tumor activity, the lowest concentration of PTX 
should be used [135]. A combination of CS gel and PLGA microparticles allows the 
application of a low amount of PTX with high anti-tumor activity against mammary 
adenocarcinoma cells. More importantly, the in vivo experiment on tumor-bearing mice 
revealed that CS NPs have anti-tumor activity and loading PTX significantly diminishes 
the tumor growth and volume. In contrast, Li and colleagues prepared DTX-loaded 
thermo-responsive CS/b-glycerophosphate hydrogel (DTX-C-/P) [136]. The results of this 
study demonstrated that C-G/P has no anti-tumor effect (H22 tumor bearing-mice). This 
discrepancy is needed to be considered in subsequent studies. The second issue is the 
biodistribution of DTX-C-G/P so that these hydrogels are distributed in the heart, spleen, liver, 
lung, and kidney. Hence, a low amount of chemotherapeutic agent should be used to minimize 
adverse impacts. Besides, the resulting nanocarriers need to have great
biocompatibility. It appears that the absorption of thermal-sensitive nanocarriers occurs 
by electrostatic-mediated endocytosis [137]. The high absorption and sustained-release 
behavior result in the great anti-tumor activity of thermo-responsive nanocarriers [138].
7.3. Redox-responsive chitosan nanoparticles
Another intracellular signaling is oxidative stress and there have been attempts to 
design nanocarriers with the capability of releasing a drug in response to oxidation [139]. 
Among these nanocarriers, micellar NPs are of interest due to the redox-triggered release of 
drugs [140, 141]. Notably, this redox-mediated release depends on disulfide bonds found in the 
matrix crosslink or in auxiliary chains. A high oxidative environment leads to the stabilization 
of bonds, while the degradation of these bonds occurs in an environment containing 
antioxidant agents such as glutathione (GSH). The redox-responsive CS micelles have 
high properties in terms of intracellular release of PTX and high cytotoxicity against tumor 
cells [142]. An important point is an increase in average particle size after exposing to GSH 
so that it seems that in the highly reducing environment, the micellar structure is hardly 
found [143]. However, the tumor microenvironment has a partial impact on the size 
distribution of CS micelles. A high concentration of GSH stimulates the release of PTX 
from redox-responsive micelles. These nanocarriers demonstrated anti-tumor activity in a 
time-dependent manner due to accumulation in the cytoplasm.
8. Chitosan nanocarriers for targeted delivery
8.1. Chitosan nanoparticles for targeted PTX delivery
The enhanced incidence rate of cancer has forced to develop novel methods in cancer therapy. 
Targeted drug delivery is a smart strategy in combating cancer cells. The identification of 
receptors on the surface of cancer cells is of importance in the following targeting by 
nanocarriers. Folate receptors undergo upregulation in tumor cells, while their expression is 
low in normal cells [144]. There have been efforts to promote the potential of nanocarriers by 
targeting folate receptors [145]. It appears that CS-folic acid (FA)-deoxycholic acid (DA) 
micelles are able to mediate the receptor-targeted delivery of PTX (figure 4) [146]. Exposing 
breast cancer cells (MCF-7) into CS-FA-DA micelles led to a significant decrease in their 
viability due to increased internalization of micelles through folate receptor-mediated 
endocytosis. One of the challenges in preparation of CS micelles is the high molecular weight 
of CS that leads to its poor solubility and consequently, diminishes the biomedical application. 
The application of water-soluble CS resolves this pitfall due to its low molecular weight [107]. 
For instance, o-carboxymethylated CS (OCMC) is an amphiphilic derivative of CS with the 
capability to be used in the synthesis of micelles [147]. The same strategy has been made by 
Cheng and colleagues [148]. They prepared FA-cholesterol-CS (FACC) micelles for delivery 
of PTX in the treatment of cervix cancer. The importance of this study was the pH-triggered 
release of PTX at the mildly acidic pH of the tumor microenvironment. Taking everything into 
account, using CS nanocarriers with the capability of targeting folate receptors is beneficial in 
terms of improving the delivery of PTX into cancer cells. This delivery is induced by folate 
receptor-mediated endocytosis [149-151]. Another important surface receptor is transferrin 
(TF). TF receptors (TFRs) stimulate iron absorption via endocytosis and exocytosis [152]. The 
upregulation of TFRs manifests the high cellular growth [153], and a variety of nanocarriers 
have been designed to target these surface receptors. TF/PEG/OCMC/fatty acid/PTX 
(TPOCFP) micelles have been developed for targeting TFRs [154]. TPOCFP micelles 
remarkably enter the nucleus by binding into surface receptors. The high cellular uptake and 
prolonged-release behavior lead to the high cytotoxicity of TF-functionalized NPs against 
cancer cells [155]. Attachment of glycol chain into CS produces NPs with high cellular uptake 
through clathrin-mediated endocytosis, caveola and macropinocytosis that is in favor of 
delivery of chemotherapeutic agents like PTX and enhancing anti-tumor activity [156]. In order 
to improve the delivery efficiency of glycol-CS NPs and generate composite NPs, anionic 
heparin can be used to interact with positively charged glycol CS, leading to the high anti-
tumor activity and targeted drug delivery [157]. Another major importance of heparin 
modification is cytotoxicity concern. Polycation NPs suffer from a number of drawbacks and 
it seems that low biocompatibility is the most important one. Neutralizing this positive charge 
can resolve this difficulty and heparin modification (negative charge) is the best option. 
Although other negatively charged agents can be applied in neutralizing the positive charge, 
the interest into heparin emanates from this fact that heparin modification provides the targeted 
delivery of NPs by tumor cells overexpressed heparanase [158]. 
Hyaluronic acid (HA) receptors, known as CD44, are exclusively overexpressed on cancer cells 
[159]. As one of the most malignant cancer cells, the incubation of breast cancer cells with CS-
hyaluronan-coated solid lipid NPs led to decreased viability and proliferation of cancer cells. 
This high anti-tumor activity is a consequence of the great cellular uptake of these nanocarriers 
by HA receptors. Overall, targeted delivery systems are able to improve the anti-tumor efficacy 
of PTX exponentially [160]. 
8.2. Chitosan nanoparticles for targeted DTX delivery
The same strategy is used for DTX delivery. Targeted delivery is of importance in lung cancer
therapy due to its high malignancy [161]. Epidermal growth factor receptor (EGFR) 
is responsible for the invasion and metastasis of lung cancer cells. Besides, the upregulation 
of EGFR occurs in lung cancer and further targeting is of interest in terms of diminishing 
the viability and proliferation of cancer cells [162, 163]. The DTX-loaded CS NPs targeting 
EGFR are capable of significantly reducing the malignancy of lung cancer cells by induction 
of G2/M phase arrest and stimulation of apoptosis and necrosis via diminishing the 
mitochondrial membrane potential [164]. This great anti-tumor activity is a consequence of 
high cellular uptake of NPs through EGFR.
In a study, Poudel and colleagues designed novel biotinylated CS-decorated DTX-
loaded nanocochleates (BI-CHI-DTX-NCs) for breast cancer therapy [165]. The NCs are 
a kind of liposomes that phospholipid is affected by divalent cation, leading to the formation 
of a roll of stacked sheets [166]. NCs have great properties in terms of high biocompatibility, 
great potential in drug delivery and affordable synthesis [167, 168]. On the other hand, BI 
receptors undergo upregulation in various cancers such as breast cancer [169]. So, BI-CHI-
DTX-NCs should have a combination of the mentioned properties. Surprisingly, NCs 
demonstrated high efficiency in encapsulating DTX by making hydrogen-binding. 
Besides, NCs exhibited a pH-dependent release of DTX at mildly acidic pH 
(pH=5.3) similar to the acidic pH of the tumor microenvironment. BI-CHI-DTX-NCs 
had high anti-tumor activity against MCF-7 breast cancer cells. Notably, in addition to the 
potential role of BI in enhancing the cellular uptake of NPs, NC has a remarkable effect itself 
by providing direct interaction with the cell membrane of cancer cells or phagocytosis [170].
Prostate-specific membrane antigen (PSMA) is a potential target in prostate cancer therapy due
to its overexpression and relation with invasion and malignancy [171-174]. Glycol-CS micelles
targeted PSMA have high anti-tumor activity due to their great cellular uptake through 
receptor-mediated endocytosis [175]. Another option in cancer therapy is targeting 
angiogenesis. It has been demonstrated that angiogenesis is associated with the high 
proliferation of tumor cells. Drug delivery systems have been designed for the inhibition of 
angiogenesis [176]. Studies have shown that GX1 can be beneficial in the inhibition of human 
gastric cancer (GC) angiogenesis [177, 178]. This inhibitory impact is exerted by specific 
binding of GX1 to endothelial cells and stimulation of apoptosis [179, 180]. It seems that DTX-
loaded CS NPs containing GX1 can be applicable for favorable treatment of GC by both 
exerting anti-tumor activity and suppressing angiogenesis [181].
One of the challenges faced in the delivery of DTX is the low stability of synthesized CS
nanocarriers. In order to overcome this problem, binding a glycol chain into CS is associated
with the great stability of CS NPs [182]. Overall, it appears that more attempts have been made
in targeted delivery of DTX compared to the PTX with more kinds of receptors. Efforts have
been directed into synthesizing CS NPs with great biocompatibility and high cellular 
uptake [183, 184]. However, the high average particle size of CS NPs is a major problem, 
resulting in their low efficacy and also high clearance by phagocytosis system.
9. Chitosan as co-delivery system
Using a combination of several of anti-tumor drugs is currently common in cancer therapy. On
one hand, this strategy diminishes the chance of resistance of tumor cells. On the other hand, 
it enhances the anti-tumor potential. In addition to the co-delivery of anti-tumor drugs, 
gene therapy can be considered as a potential candidate. In respect to the gene mutations in 
cancer progression, co-delivery of an anti-tumor drug and gene seems beneficial [185, 
186]. DNA, RNA, short interfering RNA (siRNA), microRNA (miR), locked nucleic 
acid (LNA) and plasmid DNA (pDNA) can be loaded on NPs [187]. One of the commonly 
used combinations in cancer therapy is the application of PTX and doxorubicin (DOX). It is 
noteworthy to mention that alginate (Alg) coated CS hollow nanosphere (ACHN) is able 
to remarkably improve the anti-tumor potential of PTX and DOX [188]. ACHN has great 
biocompatibility so that ACHN a the concentration of 5 ฀g/ml to 500 ฀g/ml is well-tolerated 
and just diminishes the viability of cells by 20%. Besides, the co-delivery of PTX and 
DOX by ACHN has higher anti-tumor activity compared to the PTX-DOX. This great anti-
tumor activity is a result of high cellular uptake by cancer cells and synergistic impact of PTX 
and DOX. Carbon nanotubes (CNTs) have opened a novel perspective in medicine 
because of their characteristic features. Currently, they are extensively applied in gene 
delivery, cellular imaging, biosensor, cancer therapy and so on [189, 190]. There 
have been efforts to use CS functionalized-CNTs for co-delivery of PTX and DOX in 
order to promote their anti-tumor activity [191]. Notably, both PTX and DOX drugs can be 
loaded on CNTs. The attachment of DOX is performed by binding to the aromatic surface of 
the CNTs via it-it stacking, while PTX binds to the benzene ring via it-it stacking. One of the 
challenges in the functionalization of CNTs is the adverse effects on the stability and 
biocompatibility [192]. CS functionalization offers no harmful effect on the stability and 
functionalization of CNTs by providing noncovalent functionalization. At the tumor 
microenvironment, the release of DOX and PTX occurs due to the protonation of CS that in 
turn, weakens the attachment of DOX and PTX. It appears that CS functionalized-CNTs have 
the efficiency of delivery of anti-tumor drugs (figure 5). Plant-derived chemicals are 
extensively used in chemotherapy due to their great physiological activities [27, 193, 194]. 
Berbamin (BB) is a naturally occurring nutraceutical compound with high anti-tumor activity. 
DTX- and BB-loaded CS NPs have demonstrated great capability in the stimulation of 
apoptotic cell death and down-regulation of survivin. This is due to the higher bioavailability 
of DTX and BB [195]. The studies suggest that CS functionalization not only improves the 
biocompatibility of NPs but also may provide a pH-triggered release. So, CS can be considered 
as a potential candidate in the delivery of PTX and DTX [196-198]. Gene delivery can be 
applied for enhancing the cellular uptake of PTX-loaded CS NPs. Such a strategy can be 
achieved by co-delivery of MDR1 siRNA and PTX using low density lipoprotein (LDL)-
coupled N-succinyl CS (NSC) lipoid acid (PTX-siRNA/LDL-NSC-LA) micelles [199]. Breast 
cancer cells have a high expression of LDL-receptor and have great sensitivity to LDL
micelles. The carboxyl group of NSC-LA provides a reaction with LDL, leading to 
its attachment to micelles. Although the role of LDL is great, MDR1 siRNAs also 
plays a remarkable role in cellular uptake of PTX. As it was mentioned, P-gp inhibits the 
entering of chemotherapeutic agents into cancer cells. MDR1 siRNA results in down-
regulation in the expression of mdr1 and P-gp, improving the cellular uptake of PTX.
Another privilege of CS is providing a platform for conjugation of aptamers. As 
newly introduced synthetic DNA or RNA molecules, aptamers have demonstrated excellent 
specificity towards target [200]. Aptamer-conjugated CS NPs enhance the co-delivery of DTX 
and insulin-like growth factor receptor 1 (IGF-1R) siRNA into breast cancer cells [201]. 
Anti-mucin 1 (MUC1) was applied as an aptamer due to the upregulation of MUC1 on the 
breast epithelial cells [202]. CS is not only associated with the biocompatibility of these 
nanocarriers but also provides a platform for conjugation of the aptamer. By improving the 
targeted delivery of DTX and IGF-1R siRNA, high cellular uptake of DTX significantly 
diminishes the viability and proliferation of breast cancer cells and a decrease in cell growth 
and survival is observed due to inhibition of IGF-1R. Taking everything into account, it seems 
that CS modification of NPs has two major advantages: A) improving the biocompatibility of 
NPs, and B) providing a platform for attachment of drugs and genes [203-205].
10. Imaging and theranostics applications of chitosan here
NPs have attracted much attention in the field of imaging [186]. Simultaneous imaging and 
drug delivery are of interest in cancer therapy and NPs provide minimally invasive imaging 
[206]. In line with this strategy, Bano and colleagues synthesized PTX-loaded magnetic 
nanocomposites with folate modified CS/carboxymethyl surface [207]. CS served as a platform 
for loading PTX and folate improved the cellular uptake of NPs through receptor-mediated 
absorption. Besides, CS provided the stability and protection of drug against degradation or 
oxidation. It seems that the external magnetic field enhances the anti-tumor activity of these 
nanocarriers. It is likely that this improvement was caused by controlling the directional 
movement of magnetic carriers via the external field as also reported by Xue et al. [208]. 
Nevertheless, this finding demonstrates that these NPs have a magnetically guided drug 
delivery function. Notably, it was found that the high labeling potential of these nanocarriers is 
a consequence of high cellular uptake due to using CS and folate. CS-stabilized gold NPs (CS-
AuNPs) are able to be applied for photoacoustic imaging (PAI) of cancer cells [209]. CS-
AuNPs served as contrast agents and PAI effectively provided image-guided cancer therapy 
(figure 6). This strategy has demonstrated satisfactory results while using PTX for 
chemotherapy.
11. Chitosan nanoparticles for oral delivery of PTX and DTX
Protection against degradation and improving absorption are two major goals in the 
oral administration of chemotherapeutic agents such as PTX and DTX by CS nanocarriers 
(figure 7) [210]. CS-functionalized micelles promote the cellular uptake of PTX through 
clathrin- and caveolae-mediated endocytosis [173]. Application of amphiphilic CS 
derivatives such as N- deoxycholic acid-N, O-Hydroxyethyl CS or carboxymethyl CS is 
beneficial in the development of NPs for delivery of PTX due to their low molecular weight, 
resulting in NPs with great properties such as high biocompatibility and excellent potential 
for drug delivery [211, 212]. Designing N-octyl-N'-phthalyl-O-phosphoryl CS micelles 
improve the accumulation of PTX in Caco-2 cells through caveolin-mediated endocytosis 
[213]. However, one of the most challenges of CS NPs is their low cellular uptake in animal 
models. It seems that 3,b-O, O'-dimyristoyl CS (DMC) is not beneficial in improving the 
absorption of PTX upon oral administration. This drawback is due to the mucoadhesive 
feature of CS so that DMC NPs make a tough attachment with the mucus layer secreted by 
HT29-MTX cells, leading to the inhibition of penetration of PTX-loaded CS NPs into cell 
monolayer [214]. These formulations significantly increase the bioavailability of PTX and 
subsequently, result in higher anti-tumor activity compared to the PTX alone [215-221]. The 
same story occurs in DTX delivery. Thiolated CS-functionalized NPs are potential
candidates in delivery of DTX [222, 223]. These nanocarriers are associated with enhanced
cellular uptake of DTX by opening tight junctions. It is noteworthy to mention that solid lipid
NPs (SLNs) enhance the penetration of drugs into the intestinal epithelial layer [224, 225]. 
With respect to the capability of CS in opening the tight junctions between cells [226, 
227], CS-functionalized SLNs are able to incredibly promote the permeabilization of DTX 
[228]. Notably, in vivo experiments confirm the higher anti-tumor activity of DTX-loaded CS 
NPs compared to the DTX alone, while these nanocarriers have minimal adverse impacts 
[229]. Conjugation of cyclodextrins (CDs) into CS is an efficient strategy in enhancing the 
delivery of DTX. This is due to the potential role of CDs in improving the solubility of 
DTX and protection against degradation, whereas CS opens tight junctions to elevate cellular 
uptake of DTX [230].
12. Conclusion and remarks
At the present review, we described the various CS functionalized-NPs for the delivery of PTX
and DTX (table 1,2). NPs can be considered as potential candidates in the delivery of PTX and
DTX and have demonstrated great potentials such as high biocompatibility, drug loading, EE 
and anti-tumor activity. Although the particle size distribution of synthesized CS NPs is 
uniform, the average particle size should be considered in the following studies. Self-assembled 
CS micelles can protect PTX and DTX against degradation and release these potent 
chemotherapeutic agents in a prolonged-release behavior. Similarly, microstructures provide 
the sustained release of PTX and DTX. It appears that the development of stimuli-responsive 
NPs provided dramatic progress in cancer therapy and until now, pH-, redox- and 
thermos-responsive CS NPs have been designed for the delivery of PTX and DTX. An 
important strategy in enhancing the anti-tumor potential of PTX and DTX is using targeted 
delivery systems. Folate, TF, and CD44 receptors have been targeted by CS NPs and 
findings have disclosed satisfactory results in terms of elevating cellular uptake of PTX 
and DTX. Unfortunately, we have witnessed a significant decrease in the anti-tumor activity 
of PTX and DTX due to the resistance of cancer cells. As a consequence, CS NPs have been 
developed in order to simultaneously deliver PTX and DTX with other anti-tumor drugs or 
genes. One of the most interesting strategies was the application of the MDR1 gene that down-
regulated P-gp, leading to the high cellular uptake of PTX and DTX by cancer cells. 
Minimally invasive image-guided delivery and image-guided cancer therapy using PAI 
are other applications of CS NPs. Besides, CS NPs are of importance in oral delivery of PTX 
and DTX by protection against degradation at the stomach, sustained-release in intestinal fluid 
and improving cellular uptake by opening tight junctions. However, more studies are needed 
to evaluate the efficiency of CS NPs for the delivery of PTX and DTX.
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Figure captions
Figure 1: The chemical structure of PTX and DOX.
Figure 2: The mechanism of action of PTX and DTX. During the physiological condition, 
there is a balance in entering and eliminating of tubulin proteins from 
microtubules. Upon administration of PTX or DTX, this balance is interrupted, and 
microtubules obtain a stabilized form, resulting in inhibition of mitosis and apoptotic cell 
death.
Figure 3: Stimuli-responsive CS NPs for delivery of PTX and DTX, and their mechanism 
of action.
Figure 4: Various CS-functionalized NPs applied in the delivery of PTX and DTX.
Figure 5: CNTs as potential candidates in the delivery of PTX and DTX.
Figure 6: The application of CS-functionalized NPs in cancer imaging and theranostics.
Figure 7: Protection against degradation in the stomach and enhancing the absorption of 
PTX and DTX through the intestine by CS NP
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Figure 1: The chemical structure of PTX and DOX.
Figure 2: The mechanism of action of PTX and DTX. During the physiological condition, there 
is a balance in entering and eliminating of tubulin proteins from microtubules. Upon 
administration of PTX or DTX, this balance is interrupted, and microtubules obtain a stabilized 
form, resulting in inhibition of mitosis and apoptotic cell death.
Figure 3: Stimuli-responsive CS NPs for delivery of PTX and DTX, and their mechanism of 
action.
Figure 4: Various CS-functionalized NPs applied in the delivery of PTX and DTX.
Figure 5: CNTs as potential candidates in the delivery of PTX and DTX.
Figure 6: The application of CS-functionalized NPs in cancer imaging and theranostics.
Figure 7: Protection against degradation in the stomach and enhancing the absorption of PTX and DTX 
through intestine by CS NPs. 
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